Navigation Links
Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
Date:10/19/2007

CHICAGO, Oct. 19 /PRNewswire/ -- Actelion Ltd (SWX: ATLN) today announced multiple presentations regarding Tracleer(R) (bosentan), including new Phase 3 data assessing the efficacy and safety of Tracleer in combination with sildenafil, and data obtained from the first 1,500 patients with pulmonary arterial hypertension (PAH) enrolled in the REVEAL(TM) (Registry to EValuate Early And Long-term PAH Disease Management) Registry. The presentations and publications are part of the proceedings at CHEST 2007, the annual meeting of the American College of Chest Physicians, being held October 20-25, 2007 at McCormick Place in Chicago, IL. The company will be exhibiting at booth # 239 in the Exhibit Hall.

The presentations and abstracts -- including date and location for each -- are as follows:

Tuesday, October 23, 2007, 12:30 p.m. - 2:00 p.m.

Session: Pulmonary Vascular Disease: Evaluation and Treatment, ID #858

Oral Presentation: REVEAL Registry: Baseline Characteristics of the First

Enrolled Patients

Location: Convention Center E264

Presenter: David Badesch, MD

Abstract #: 5982

Tuesday, October 23, 2007, 2:30 p.m. - 4:00 p.m.

Session: Pulmonary Vascular Disease: Pulmonary HTN, ID # 900

Oral Presentation: Bosentan improves hemodynamics in patients receiving

background Sildenafil treatment: results from EARLY, a randomized,

double-blind, placebo controlled study in patients with mildly

symptomatic pulmonary arterial hypertension

Location: Convention Center E266

Presenter: Lewis Rubin, MD

Abstract #: 5356

Session: Pulmonary Vascular Disease : Pulmonary HTN, ID # 900

Oral Presentation: Acute hemodynamic effect of Sildenafil in comparison

with inhaled nitric oxide in patients receiving Bosentan therapy for

pulmonary arterial hypertension (COMPASS-1)

Location: Convention Center E266

Presenter: Nazzareno Galie, MD

Abstract #: 5482

Wednesday, October 24, 2007, 12:30 p.m. - 2:00 p.m.

Session: Pulmonary Vascular Disease: Pulmonary HTN Evaluation and

Treatment, ID #893

Poster Presentation: REVEAL Registry: Treatment History and Treatment at

Baseline

Location: Convention Center, Exhibit Hall

Presenter: Michael McGoon, MD

Poster #: 585

Abstract #: 6023

Session: Pulmonary Vascular Disease: Pulmonary HTN Evaluation and

Treatment, ID #893

Poster Presentation: REVEAL Registry: Medical History and Time to

Diagnosis of Enrolled Patients

Location: Convention Center, Exhibit Hall

Presenter: C. Gregory Elliott, MD

Poster #: 584

Abstract #: 6036

Session: Pulmonary Vascular Disease: Pulmonary HTN Evaluation and

Treatment, ID #893

Poster Presentation: Goal-Directed Combination Therapy in Pulmonary

Arterial Hypertension (PAH): Study Design of COMPASS-3

Location: Convention Center, Exhibit Hall

Presenter: Fernando Torres, MD

Poster #: 573

Abstract #: 5963

About Tracleer(R) in Pulmonary Arterial Hypertension (PAH)

Tracleer(R) (bosentan), the first oral dual endothelin receptor antagonist, is approved for the treatment of pulmonary arterial hypertension (PAH) and made available by Actelion subsidiaries in the United States, the European Union, Japan, Australia, Canada, Switzerland and other markets worldwide.

Requires attention to two significant safety concerns: Potential for serious liver injury (including rare cases of liver failure and unexplained hepatic cirrhosis in a setting of close monitoring) -- Liver monitoring of all patients is essential prior to initiation of treatment and monthly thereafter. High potential for major birth defects -- Pregnancy must be excluded and prevented by two forms of birth control; monthly pregnancy tests should be obtained. Because of these risks, Tracleer is only supplied through a controlled distribution.

About Actelion Pharmaceuticals

Actelion Pharmaceuticals has pioneered research and development in the pulmonary arterial hypertension (PAH) disease area. More than 40,000 PAH patients have been prescribed Actelion's product Tracleer(R) (bosentan), an orally available dual endothelin receptor antagonist for patients with World Health Organization (WHO) Class III or IV PAH. Tracleer was approved in 2001 as the first oral treatment for PAH, and is currently approved in the U.S., the European Union, and other markets worldwide. In January 2007, Actelion acquired CoTherix, Inc., whose product Ventavis(R) is approved and marketed in the United States for the treatment of patients with NYHA Class III or IV PAH.


'/>"/>
SOURCE Actelion Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):